Long-term treatment with interferon β-1a evaluated

被引：0
|
作者：
Hausmann, Ralph
机构：
来源：
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE | 2007年 / 75卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [1] Pharmacodynamic Biomarkers of Interferon β-1a: Assessment in Patients Receiving Long-Term Treatment with Subcutaneous Interferon β-1a
    Freedman, Mark
    Wojcik, Jerome
    D'Antonio, Mauro
    Hyvert, Yann
    Stinchi, Sofia
    D'Urso, Vittorio
    Dangond, Fernando
    NEUROLOGY, 2020, 94 (15)
  • [2] Pharmacodynamic biomarkers of interferon β-1a: assessment in patients receiving long-term treatment with subcutaneous interferon β-1a in REFLEX and REFLEXION
    Freedman, M. S.
    Wojcik, J.
    D'Antonio, M.
    Hyvert, Y.
    Stinchi, S.
    D'Urso, V.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 769 - 770
  • [3] Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a:: long-term results
    Ghezzi, A.
    Amato, M. P.
    Capobianco, M.
    Gallo, P.
    La Mantia, L.
    Marrosu, M. G.
    Martinelli, V.
    Milani, N.
    Milanese, C.
    Moiola, L.
    Patti, F.
    Pozzilli, C.
    Trojano, M.
    Zaffaroni, M.
    Comi, G.
    NEUROLOGICAL SCIENCES, 2007, 28 (03) : 127 - 132
  • [4] Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a: long-term results
    A. Ghezzi
    M. P. Amato
    M. Capobianco
    P. Gallo
    M. G. Marrosu
    V. Martinelli
    C. Milanese
    L. Moiola
    N. Milani
    L. La Mantia
    F. Patti
    C. Pozzilli
    M. Trojano
    G. Comi
    M. Zaffaroni
    Neurological Sciences, 2007, 28 : 127 - 132
  • [5] Long-term benefits of early and high douses of interferon β-1a treatment in relapsing-remitting multiple sclerosis
    Chofflon, M
    Ben-Amor, AF
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) : 244 - 248
  • [6] PRISMS-4:: Long-term efficacy of interferon-β-1a in relapsing MS
    Francis, G
    Hughes, R
    King, J
    Mitchell, P
    Joubert, J
    McLeod, J
    Parker, G
    Pollard, J
    Sindic, CJM
    Duprez, T
    Medaer, R
    Broeckx, J
    Vanroose, E
    Carton, H
    Wilms, G
    Rice, G
    Ebers, G
    Lee, DH
    Freedman, M
    Nelson, R
    Rabinovitch, H
    Christie, S
    Avruch, L
    Oger, J
    Paty, DW
    Li, D
    Wikström, J
    Salonen, OLM
    Panelius, M
    Erälinna, J
    Sonninen, P
    Rieckmann, P
    Hahn, D
    Flachenecker, P
    Hartung, HP
    Uitdehaag, B
    Bertelsmann, FW
    Barkhof, F
    Hommes, OR
    Jongen, PJH
    Van Doorn, PA
    Tanghe, HLG
    Sandberg-Wollheim, M
    Larsson, EM
    Lönntoft, M
    Sallerfors, S
    Kappos, L
    Lienert, C
    Radü, EW
    Chofflon, M
    NEUROLOGY, 2001, 56 (12) : 1628 - 1636
  • [7] Associations between annualized relapse rate and long-term exposure to subcutaneous interferon β-1a in the Prevention of Relapses and disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) long-term follow-up study
    Uitdehaag, B.
    Constantinescu, C.
    Cornelisse, P.
    Jeffery, D.
    Kappos, L.
    Li, D.
    Sandberg-Wollheim, M.
    Traboulsee, A.
    Verdun, E.
    Rivera, V.
    JOURNAL OF NEUROLOGY, 2010, 257 : S148 - S148
  • [8] Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis -: An econometric model
    Lepen, C
    Coyle, P
    Vollmer, T
    Blumhardt, L
    Lilliu, H
    Beresniak, A
    CLINICAL DRUG INVESTIGATION, 2003, 23 (09) : 571 - 581
  • [9] Long-Term Cost Effectiveness of Interferon-β-1a in the Treatment of Relapsing-Remitting Multiple SclerosisAn Econometric Model
    Claude Lepen
    Patricia Coyle
    Timothy Vollmer
    Lance Blumhardtf
    Hervé Lilliu
    Ariel Beresniak
    Clinical Drug Investigation, 2003, 23 : 571 - 581
  • [10] ADVERSE REACTIONS IN LONG-TERM INTERFERON TREATMENT
    LEVENS, WJ
    FISCHER, N
    INGEHAG, W
    RUBBEN, H
    SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (03): : 204 - 206
12345